Nelson Advisors: Strategic Analysis of Heidi II - Ambient Voice Technology (AVT) to Autonomous Clinical Operating System
Executive Overview: The Structural Inflection in Clinical AI
The digital health sector is experiencing a structural paradigm shift as clinical artificial intelligence evolves from passive ambient voice scribing into active, autonomous administrative agents. First generation ambient voice technology (AVT) demonstrated proven utility by capturing multi party dialogue in the consultation room and summarising encounter notes, thereby reducing electronic health record (EHR) data entry burnout.
However, passive scribing addresses only an isolated portion of the clinical overhead burden. Contemporary healthcare practitioners spend an average of 8.7 hours per week, representing roughly 16.6% of their total professional working hours navigating between four and six fragmented administrative software applications to complete work generated outside the direct clinical encounter.
On September 28th, 2026, Melbourne founded clinical AI company Heidi Health unveiled Heidi II, an upgraded platform architecture designed to transform the product from an ambient documentation assistant into an autonomous clinical operating system. Rather than limiting its scope to transcribing conversations, Heidi II deploys autonomous agents capable of executing multi-step administrative workflows across existing practice management infrastructure. These agents operate across clinical schedules to pre-chart patient panels, triage incoming pathology reports, compose specialised referral communications and conduct asynchronous panel sweeps for preventative screenings and recalls.
The product rollout follows a major capitalisation event: a US$340 million financing package announced in late September 2026, comprising a US$100 million Series C equity round led by Blackbird Ventures at a US$900 million post-money valuation, alongside a US$240 million growth financing investment from General Catalyst’s Customer Value Fund. This capital expansion builds on rapid financial scale, with Heidi Health expanding its annual recurring revenue (ARR) from US$1 million to US$50 million within a 24 month period ending in April 2026, while supporting 2.8 million weekly patient interactions across 190 countries and 110 languages.
Heidi II’s multi step agents are designed to interface across local practice software, yet its deployment highlights an emerging international regulatory divide. While rolling out globally in English and French starting September 29th, 2026, specific autonomous agentic capabilities face deliberate geographic restrictions within the United Kingdom and the European Union, where statutory medical device classifications, clinical decision support rules and AI safety regulations impose strict governance thresholds.
Technical Architecture and Multi Step Agentic Mechanics
The architectural core of Heidi II transitions clinical workflow automation from sequential, prompt dependent large language model (LLM) pipelines into an asynchronous multi agent execution environment.
First generation ambient scribes operate along a rigid linear trajectory: acoustic audio streams are captured, transformed into text via automatic speech recognition (ASR), passed through a centralised LLM for structured summarisation and manually transferred by the clinician into the EHR.
Heidi II replaces this single encounter framework with a tripartite architectural foundation combining background autonomous agents, persistent longitudinal memory and direct integration with peer reviewed research databases.
At the user interface level, the platform introduces a redesigned "Home" workspace that functions as a clinical operating hub. Upon opening, the system loads the clinician's entire daily roster, consolidating appointment queues, active sessions and outstanding administrative tasks with relevant longitudinal context pre populated from practice records. Clinicians interact with the system via natural language instructions, directing the platform to complete complex, multi-layered administrative assignments without requiring iterative, step by step guidance.
Once an instruction is issued, the platform initialises an autonomous agent that plans the sequence of technical operations, retrieves necessary historical and laboratory parameters from connected systems, executes the task in the background and returns a verified draft for review. The architecture incorporates explicit operational bounds: when an agent encounters ambiguous clinical parameters, conflicting chart histories, or system access constraints, it immediately halts execution, surfaces the specific point of failure and provides a clear explanation of why the action could not be completed autonomously.
Interoperability across legacy clinical technology is facilitated by bidirectional software connectors. These connectors enable agents to navigate and interact across diverse environments, including EHR databases, practice management calendars, secure clinical messaging inboxes and patient communication portals. Agents read and process structured appointment rosters, cross reference diagnostic archives, compose outbound correspondence aligned with institutional Standard Operating Procedures (SOPs) and stage entries directly within practice billing and scheduling workflows.
To support acoustic reliability in varied physical environments, the software architecture interfaces with Heidi Remote, an enterprise-grade hardware audio device introduced earlier in 2026. The dedicated hardware mitigates environmental acoustic interference, ensuring high fidelity signal capture that minimises downstream word error rates (WER) prior to domain specific natural language processing.
Operational Capabilities: Longitudinal Memory, Pre Charting and Panel Wide Routines
The operational shift introduced by Heidi II targets the post encounter task burden that characterises contemporary clinical practice. Company operational metrics show that its 2.8 million weekly patient encounters generate roughly 10 million administrative follow up tasks every week, surpassing 400 million discrete tasks since early 2024. Under conventional practice arrangements, these tasks must be addressed between appointments or after clinic hours. Heidi II structures these duties into coordinated, repeatable agentic operations at both the individual patient and clinic wide panel levels.
Prior to a scheduled consultation, the agent conducts automated pre-charting across the daily roster. The agent navigates the EHR, retrieves prior clinical encounters, reviews recent laboratory and pathology feeds, isolates interval changes in patient status and generates a structured pre visit summary designed to be reviewed by the clinician in under 30 seconds. This process eliminates manual chart preparation, ensuring that providers enter consultations with full clinical context.
When external diagnostic reports arrive, the system matches incoming pathology and imaging files against corresponding patient records. It evaluates abnormal values against established reference ranges and historical baselines, correlates the findings with previous consultation transcripts and drafts context aware clinical communications or specialist referrals for provider approval.
Beyond single patient administrative handling, Heidi II introduces "Routines," which represent scheduled, batch-processed agentic workflows configured for individual clinicians or entire multi provider practices. Instead of processing records sequentially, Routines execute asynchronous sweeps across full patient panels to maintain longitudinal care compliance.
Panel sweeps systematically analyse practice populations to identify individuals due for routine surveillance tests, such as diabetic HbA1c panels, renal function monitoring for high-risk pharmacotherapies, overdue paediatric vaccinations, or statutory cancer screenings. The agent compiles verified lists of overdue patients, drafts personalised recall communications, stages appointment invitations within clinic portals and presents the entire batch to the care team for bulk authorisation.
Operational Dimension | First-Generation Ambient Scribes (e.g., Heidi I, Dictate IT) | Autonomous Administrative Agents (Heidi II) |
Primary Functional Scope | Passive transcription, consultation summariaation, and SOAP note generation. | Autonomous multi-step administrative execution, pre-charting, diagnostic triage, and panel sweeps. |
System Interoperability | One-way output copy/paste or basic API write-back to encounter notes. | Deep, multi-system desktop interaction across EHRs, clinic calendars, mail inboxes, and portals. |
Execution Cadence | Synchronous to the patient visit; triggered sequentially per encounter. | Asynchronous and continuous; capable of scheduled, batched "Routines" across entire patient panels. |
Context Window & Memory | Isolated to the immediate consultation audio buffer. | Persistent practice memory, attaching prior visits, cross-system EHR files, and longitudinal patient charts. |
Knowledge Grounding | Unconstrained base LLM generation; risk of clinical hallucination. | Real-time retrieval-augmented generation tied to peer-reviewed literature (NEJM, BMJ, Cochrane, Wiley). |
Regulatory Footprint | Predominantly exempt or low-risk Class I administrative software. | Class I transitioning toward Class IIa medical device frameworks due to contextual clinical orchestration. |
Clinical Safety Engineering and Governance via Deliberate Friction
Deploying autonomous agents within live clinical environments creates distinct patient safety risks, including algorithmic hallucinations, omission of critical secondary diagnoses and provider automation bias. When administrative agents are granted access to execute tasks across patient panels and medical records, an undetected software error could propagate across hundreds of clinical files. To address this failure mode, Heidi Health designed its architecture around the operational principle of "deliberate friction".
Deliberate friction requires that no agentic action commit directly to the legal medical record or trigger an unreviewed outbound patient communication. Agents execute data gathering, cross-referencing, synthesis, and drafting autonomously in the background, but present all completed actions within an interactive sign-off queue inside the Home dashboard. Clinical authority remains strictly with the clinician, who must explicitly validate, modify, or reject every draft note, diagnostic summary, referral letter and recall order.
To enable rapid verification without adding cognitive fatigue, the user interface displays generated outputs alongside the original source data, such as side by side views of consultation transcripts or underlying laboratory reports.
Platform governance is reinforced by specialised internal clinical safety teams that evaluate each feature through clinical risk management frameworks before and after deployment. Heidi Health maintains formal compliance with UK clinical safety standards DCB0129 (Clinical Risk Management: Its Application in the Deployment and Use of Health IT Systems by manufacturers) and DCB0160 (health organisation deployment risk management), maintaining structured hazard logs, risk mitigation dossiers, and oversight by a nominated Clinical Safety Officer (CSO).
The platform’s data governance framework complies with the international AI management standard ISO/IEC 42001, information security certifications ISO 27001 and Cyber Essentials Plus, SOC 2 Type II attestations, HIPAA and GDPR/UK GDPR requirements. Patient privacy is protected via an ephemeral processing model: consultation audio is processed in real time and permanently purged immediately following transcription, preventing historical audio archiving. Transcripts and generated records undergo automatic de-identification, and user data is contractually isolated from training generalised commercial foundation models.
Grounded Medical Intelligence: Point of Care Peer Reviewed Evidence Integration
A primary clinical risk in deploying generative AI in healthcare is model drift and ungrounded generation, where language models invent diagnostic criteria, state inaccurate drug interactions, or reference fabricated medical literature. Heidi II addresses this vulnerability by embedding direct integrations with verified peer-reviewed clinical research databases and clinical decision support systems directly into its conversational and agentic workflows.
The platform establishes content integrations with established medical knowledge providers, including The New England Journal of Medicine (NEJM), the Cochrane Database of Systematic Reviews, Wiley’s scientific publications, and BMJ Group’s clinical decision support databases. Rather than functioning as a disconnected reference search bar, this medical evidence layer is woven directly into the agent’s execution loop.
When Heidi II plans a clinical task, such as analysing an atypical pathology result, drafting a complex subspecialty referral, or reviewing a clinical visit, it queries these medical repositories using retrieval-augmented generation techniques. The agent grounds its recommendations in verified guidelines, returning synthesis summaries accompanied by contextual, inline citations.
Clinicians who hold subscriptions to these respective journals can select embedded citations to navigate directly to the underlying full text studies, clinical trial data, or systematic reviews. This direct link bridges routine administrative work with evidence based medicine, allowing clinicians to review clinical justification without leaving their documentation workflow.
This evidence architecture expands upon Heidi Evidence, a standalone reference module launched in March 2026 that processed more than 10 million clinical queries prior to its incorporation into the Heidi II platform.
Capitalisation Profile, Growth Metrics and Corporate Scale
The commercial rollout of Heidi II is supported by a US$340 million financing transaction finalised in late September 2026, which increased the company’s total cumulative capitalisation to US$436.6 million across five financing rounds since its founding in 2019.
The transaction is structured across two distinct financial instruments designed to balance technical innovation with balance sheet capacity. The first component is a US$100 million Series C equity round led by Blackbird Ventures, with continued investment from Phoenix Court (LocalGlobe, Latitude), Point72 Private Investments, and Headline. This equity tranche established Heidi Health’s post-money valuation at US$900 million. The equity capital is directed primarily toward proprietary model research and development, expanding task-specific foundation models, and securing clinical device certifications across major regulatory jurisdictions.
The second component consists of a US$240 million non-dilutive growth financing investment from General Catalyst’s Customer Value Fund (CVF). The CVF mechanism functions as revenue linked growth capital, providing enterprise balance sheet resources to fund large scale deployments, support customer acquisition costs for multi site health systems, deploy forward deployed technical engineering squads and execute complex enterprise migrations without diluting company equity.
Metric Category | Recorded Performance Metric | Operational Context and Strategic Relevance |
Total Transaction Package | US$340 Million | Blended financing: US$100M Series C equity and US$240M non-dilutive CVF. |
Post-Money Valuation | US$900 Million | Represents valuation expansion driven by the transition from scribing to an agentic clinic OS. |
Cumulative Funding | US$436.6 Million | Total institutional capital secured since incorporation in 2019. |
Annual Recurring Revenue | US$50 Million ARR | Achieved in April 2026; expanded from US$1M ARR in April 2024 (50x increase in 24 months). |
Weekly Active Encounters | 2.8 Million visits/week | Global deployment across 190 countries in 110 languages. |
Total Historical Volume | >175 Million visits; >67 Million hours saved | Longitudinal dataset informing domain-specific clinical transcription models. |
Weekly Generated Tasks | ~10 Million tasks/week | Administrative overhead volume targeted for autonomous agent execution. |
Anchor Institutional Awards | NHS England Midlands Framework | Named sole supplier across 1,239 GP practices and 15 trusts serving ~70,000 clinicians. |
Heidi Health’s revenue growth from US$1 million to US$50 million ARR between April 2024 and April 2026 reflects significant institutional enterprise adoption. In early 2026, Heidi Health was selected as the sole supplier in the NHS England Midlands framework tender, managed by The Dudley Group NHS Foundation Trust and Sandwell and West Birmingham Hospitals.
This framework represents the largest single ambient clinical AI procurement in NHS history, covering up to 70,000 clinicians across 1,239 general practices, 15 acute and community trusts and all regional Integrated Care Boards (ICBs). Pilot data from The Dudley Group indicated that platform deployment cleared a six month outpatient rheumatology correspondence backlog within 14 days and reduced documentation time in Same Day Emergency Care (SDEC) departments by 80%.
In the North American market, Heidi Health operates enterprise agreements with Beth Israel Lahey Health and MaineGeneral Health, supported by a regional operating headquarters in Toronto to accelerate expansion across the United States and Canada.
Competitive Stratification Across the Ambient Intelligence Market
The healthcare AI documentation landscape is undergoing rapid consolidation, splitting the market into distinct technological tiers and exposing point solution transcription tools to commoditisation risks. Pure play scribing platforms that function solely as wrapper layers over generic, third party LLMs face margin compression, rising compute licensing costs and defensive feature additions by incumbent EHR vendors.
In response, market leaders are establishing specialised moats based on deep workflow automation, integrated revenue cycle management, proprietary foundation models, and regional regulatory compliance.
Vendor | Primary Geographic Focus | Total Funding & Valuation Benchmark | Architectural Strategy & Regulatory Profile | Core Competitive Differentiation |
Heidi Health (Heidi II) | Global (US, UK, ANZ, Canada, Europe) | $436.6M total raised; $900M valuation | Task-specific foundation models; Class I documentation; staged Class IIa pathways; ISO 42001/27001. | Autonomous agentic "Routines"; integrated NEJM/BMJ research base; sole supplier for NHS Midlands (1,239 GP practices). |
Abridge | United States (Enterprise Health Systems) | >$730M raised; $5.3B valuation (Series E) | Deep enterprise EHR integration; proprietary audio mapping; focused on US commercial billing/HIPAA. | Strong enterprise market share among US academic medical centers; highly optimised for US fee for service coding and RVU generation. |
Tandem Health | European Union & UK | $160M raised; $100M Series B | Holds 3 CE-marked EU MDR Class IIa certifications; localized across 14 languages; native EU data residency. | Deep localisation within European health systems; integrated across 130+ European EHRs; robust regulatory moat under EU MDR. |
Tortus AI | United Kingdom (NHS Trusts) | £3.4M Seed round; backed by Khosla Ventures | UKCA Class IIa medical device; O.S.L.E.R. clinical agent; NHS AVT Registry; MHRA AI Airlock participant. | Focus on acute clinical secondary care; validated in trials with Great Ormond Street Hospital; telephony integration via X-on Health. |
Incumbent EHRs (Epic, Oracle Health / Microsoft Nuance DAX) | Global Enterprise Healthcare Systems | Multi billion market capitalisation incumbents | Native embedding within core hospital information systems (Epic Rover/Hyperdrive, Cerner Millennium). | Unmatched access to institutional clinical records and embedded vendor contracts; offset by slower product release cycles. |
Heidi Health's competitive posture relies on high volume, cross border distribution supported by product led growth. While Abridge has concentrated on large, capital-intensive US hospital networks and commercial coding optimisation, Heidi Health’s presence across 190 countries provides access to diverse clinical data streams across primary, secondary, and allied health settings.
However, Heidi Health faces distinct regional challenges. In continental Europe, Stockholm based Tandem Health has established a defensive regulatory position, securing three EU MDR Class IIa medical device certifications and integrating directly with more than 130 regional European EHR architectures, including private hospital networks like Ramsay Santé.
Simultaneously, within the UK NHS acute hospital sector, early-stage entrants such as Tortus AI have focused on Class IIa medical device compliance from inception, establishing partnerships with acute NHS trusts to evaluate complex, multi specialty workflows.
Regulatory Bifurcation and International Compliance Barriers
The rollout structure of Heidi II, launching initially in English and French while restricting specific agentic capabilities outside the United Kingdom and the European Union, highlights a clear divide in how different jurisdictions govern clinical AI software. While market frameworks in North America and Australasia largely permit administrative task execution under human review, the UK and EU enforce strict regulatory definitions that classify automated diagnostic triage, record synthesis and active clinical planning as medical device software.
In the United Kingdom, medical software is governed by the Medicines and Healthcare products Regulatory Agency (MHRA) under the UK Medical Devices Regulations 2002 (as amended). MHRA guidance published on July 29th, 2026, established clear boundaries for ambient voice systems:
Systems restricted to real-time speech transcription, clinical document formatting and administrative summarisation under clinician validation do not meet the legal definition of a medical device, permitting operation as non-device administrative software or low risk Class I tools. Heidi’s primary scribe operates within this Class I documentation classification.
When an AI system accesses longitudinal medical records, reviews incoming pathology and autonomously extracts patient-specific clinical parameters to generate diagnostic advice or prioritise care pathways, it transitions into Clinical Decision Support (CDS). Under UK MDR 2002, contextual CDS tools require formal registration as Class I or Class IIa medical devices, mandating demonstrated clinical performance, technical documentation and compliance with statutory risk thresholds.
This regulatory distinction previously required Heidi Health to limit Heidi Evidence in the UK and EU. Clinicians could submit general clinical inquiries outside active visits, but in-session queries that linked live consultation transcripts to specific patient records were disabled to prevent the system from crossing into regulated clinical decision-support territory.
Because Heidi II’s autonomous agents execute end-to-end tasks on identifiable patient charts, such as pre-charting and evaluating diagnostic reports, deploying these capabilities in the UK prior to updated device registration would trigger compliance liabilities for NHS trusts under clinical risk standards DCB0129 and DCB0160.
Regulatory scrutiny in the UK has also increased following a national investigation initiated on August 6, 2026, by the Health Services Safety Investigations Body (HSSIB). The HSSIB inquiry is examining the patient safety implications of ambient voice technologies in acute hospital settings, focusing specifically on risks from generative hallucinations, information omissions in multi morbid patients and clinician automation bias during high volume shifts.
Because the HSSIB's findings and statutory recommendations are scheduled for release in Summer 2027, deploying active agentic systems into the NHS without formal device certification creates commercial exposure. To prepare for this regulatory evolution, Heidi Health acquired UK-based AutoMedica in 2026, securing a position in the MHRA’s "AI Airlock" regulatory sandbox to validate and certify its autonomous agent workflows for UK healthcare environments.
Regulatory Jurisdiction | Governing Authority & Legal Basis | Medical Device & AI Classification Status | Primary Compliance Mandates & Deployment Barriers |
United States | US FDA (21 CFR Part 820; 21st Century Cures Act) | Non-Device Administrative Support Software / Exempt CDS | FDA enforcement discretion applies where providers review drafts prior to EHR commit; compliance focuses on HIPAA and BAA agreements. |
United Kingdom | MHRA (UK MDR 2002 as amended); NHS England | Class I (Documentation) transitioning to Class IIa (Agentic CDS) | MHRA guidance (July 2026) delinks scribing, but classifies in-session CDS as a medical device; requires DTAC, DSPT, DCB0129/DCB0160, and HSSIB safety review. |
European Union | EU MDR (2017/745, Rule 11); EU AI Act | Class IIa Medical Device & High-Risk AI System | Rule 11 requires notified body audit, ISO 13485 QMS, and clinical trials (€200K–€600K; 12–18 mo); requires local cloud hosting (French HDS, German C5). |
Australia | TGA (Therapeutic Goods Act 1989 / Medical Device Regs) | Class I / Excluded Clinical Software (Administrative) | TGA Feb 2026 guidance requires ARTG entry for diagnostic software; administrative workflows remain exempt under registered provider oversight. |
Within the European Union, regulatory requirements are defined by Rule 11 of Chapter III, Annex VIII of the EU Medical Device Regulation (EU MDR 2017/745). Under Rule 11, software intended to provide information used to take decisions with diagnostic or therapeutic purposes is classified as a Class IIa Medical Device.
Securing Class IIa CE-mark certification requires a formal Quality Management System audited against EN ISO 13485:2016, comprehensive Clinical Evaluation Reports (CER) grounded in clinical trial data, and review by an accredited European Notified Body. This conformity process typically demands between €200,000 and €600,000 in regulatory capital and requires 12 to 18 months of lead time.
Furthermore, autonomous agents operating in the EU are subject to the European Union Artificial Intelligence Act (EU AI Act). Software that prioritises patient lists, triages clinical communications, or assists in clinical decision-making falls under the High Risk AI System category, requiring continuous post-market risk monitoring, algorithmic transparency logging, and compliance with the ISO/IEC 42001 AI governance framework.
These requirements are compounded by strict national health data sovereignty rules, including French Hébergeur de Données de Santé (HDS) certification, the German Federal Office for Information Security (BSI) C5 criteria and Spanish Esquema Nacional de Seguridad (ENS High) standards. These frameworks mandate local EU cloud hosting and restrict data transfers to overseas infrastructure.
Given these statutory barriers, Heidi Health has restricted its initial Heidi II agentic rollout to more flexible jurisdictions, such as Australia, Canada, and the United States, while it works to secure the necessary Class IIa medical device clearances and localised data architectures in the UK and continental Europe.
Strategic Synthesis and Future Outlook
Heidi Health’s release of Heidi II represents a critical evolutionary step in healthcare software: the transition from passive documentation tools to active, autonomous administrative agents. While first generation AI scribes focused on documenting the clinical consultation, Heidi II expands AI utility into the administrative workflows that surround clinical encounters.
By combining autonomous task execution, longitudinal memory, peer reviewed medical research integration and panel-wide "Routines," the platform seeks to decouple clinical productivity from administrative burden. The company's business traction, demonstrated by US$50 million in ARR, 2.8 million weekly consultations and a US$340 million blended financing structure, indicates strong institutional demand for integrated clinical operating systems.
However, the future growth of autonomous clinical agents will depend less on raw generative capabilities and more on regulatory execution, clinical safety engineering and technical integration. As health service authorities in the United Kingdom, European Union and North America define the boundaries between administrative automation and regulated clinical decision support, the market will favour platforms that can combine autonomous utility with verified clinical safety, transparent human in the loop oversight and strict compliance with local regulatory frameworks.
Heidi Health's strategy, using non dilutive capital to fund enterprise health system rollouts while pursuing device sandbox pathways through acquisitions like AutoMedica, reflects the complex approach required to scale clinical AI agents across global healthcare markets.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Healthcare.Digital serves as a research platform for Nelson Advisors’ perspectives on deals, valuations and structural shifts reshaping Global Digital Health, MedTech, Healthcare AI and Health IT. https://www.healthcare.digital
Nelson Advisors is one of Europe's leading mergers and acquisitions advisory firms, exclusively dedicated to the dynamic and rapidly evolving healthcare technology sector. With a deep understanding of market dynamics and technological advancements, they empower innovative HealthTech companies and strategic investors to navigate complex transactions and achieve their growth ambitions. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #Genomics
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments